Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Incidental risk of malignancy in mature cystic teratoma: experience of a single tertiary center
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Ege University, 35100, Izmir, Turkey
2Department of Pathology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
DOI: 10.22514/ejgo.2023.040 Vol.44,Issue 3,June 2023 pp.71-75
Submitted: 12 March 2023 Accepted: 23 April 2023
Published: 15 June 2023
*Corresponding Author(s): Nuri YILDIRIM E-mail: nuri-yildirim@hotmail.com
We aimed to evaluate the incidental risk of malignancy in mature cystic teratomas (MCT) and check the management. We retrospectively reviewed records of patients diagnosed and treated with MCT and divided patients into two groups as pure MCT and malignant transformation of MCT. In our clinic incidence of incidental malignant transformation of ovarian MCTs was 2.7%. Median age (p = 0.005) and mass size (p = 0.027) were statistically higher in malignant group. The most common histological type of malignant transformations was malignant struma ovarii (35.7%). In malignant group, five-year disease-free survival was 66.7% and five-year overall survival was 86.7%. Although the risk of malignancy in mature cystic teratomas is rare, it should not be ignored. Age, mass size, and preoperative imaging should all be evaluated with suspicion and if available, frozen section should be used. Management is inconsistent as a result of its rarity. New management practices should be developed with further studies.
Dermoid cyst; Mature cystic teratoma; Malignancy; Malignant transformation
Ceren SANCAR,Şahla GASIMOVA,Gürdeniz SERIN,Osman ZEKIOGLU,Necmettin OZDEMIR,Levent AKMAN,Mustafa Coşan TEREK,Ahmet Aydın ÖZSARAN,Nuri YILDIRIM. Incidental risk of malignancy in mature cystic teratoma: experience of a single tertiary center. European Journal of Gynaecological Oncology. 2023. 44(3);71-75.
[1] MATZ MH. Benign cystic teratomas of the ovary. A review. Obstetrical and Gynecological Survey. 1961; 16: 591–605.
[2] Maeda K, Terai Y, Terada S, Maruoka H, Kogata Y, Ashihara K, et al. A case of ovarian clear cell carcinoma arising from ovarian mature cystic teratoma. Journal of Ovarian Research. 2018; 11: 74.
[3] RIM SY, KIM SM, CHOI HS. Malignant transformation of ovarian mature cystic teratoma. International Journal of Gynecological Cancer. 2006; 16: 140–144.
[4] Ayhan A, Bukulmez O, Genc C, Karamursel BS, Ayhan A. Mature cystic teratomas of the ovary: case series from one institution over 34 years. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2000; 88: 153–157.
[5] Wu RT, Torng PL, Chang DY, Chen CK, Chen RJ, Lin MC, et al. Mature cystic teratoma of the ovary: a clinicopathologic study of 283 cases. Chinese Medical Journal. 1996; 58: 269–274.
[6] Comerci JT Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstetrics and Gynecology. 1994; 84: 22–28.
[7] Bal A, Mohan H, Singh SB, Sehgal A. Malignant transformation in mature cystic teratoma of the ovary: report of five cases and review of the literature. Archives of Gynecology and Obstetrics. 2007; 275: 179–182.
[8] Park J, Kim D, Kim J, Kim Y, Kim Y, Nam J. Malignant transformation of mature cystic teratoma of the ovary: Experience at a single institution. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2008; 141: 173–178.
[9] Mori Y, Nishii H, Takabe K, Shinozaki H, Matsumoto N, Suzuki K, et al. Preoperative diagnosis of malignant transformation arising from mature cystic teratoma of the ovary. Gynecologic Oncology. 2003; 90: 338–341.
[10] Yamanaka Y, Tateiwa Y, Miyamoto H, Umometo Y, Takeuchi Y, Katayama K, et al. Preoperative diagnosis of malignant transformation in mature cystic teratoma of the ovary. European Journal of Gynaecological Oncology. 2005 ;26: 391–392.
[11] Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, et al. A series of malignant ovarian cancers arising from within a mature cystic teratoma. International Journal of Gynecological Cancer. 2015; 25: 792–797.
[12] Akazawa M, Onjo S. Malignant transformation of mature cystic teratoma: is squamous cell carcinoma different from the other types of neoplasm?International Journal of Gynecologic Cancer. 2018; 28: 1650–1656.
[13] Glasspool RM, Martín AG, Millan D, Lorusso D, Åvall-Lundqvist E, Hurteau JA, et al. Gynecologic cancer intergroup (GCIG) consensus review for squamous cell carcinoma of the ovary. International Journal of Gynecologic Cancer. 2014; 24: S26–S29.
[14] Futagami M, Yokoyama Y, Mizukami H, Shigeto T, Mizunuma H. Can malignant transformation in mature cystic teratoma be preoperatively predicted? European Journal of Gynaecological Oncology. 2012; 33: 662–665.
[15] Srisajjakul S, Prapaisilp P, Bangchokdee S. Imaging features of unusual lesions and complications associated with ovarian mature cystic teratoma. Clinical Imaging. 2019; 57: 115–123.
[16] Li C, Zhang Q, Zhang S, Dong R, Sun C, Qiu C, et al. Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review. BMC Cancer. 2019; 19: 217.
[17] Gainford MC, Tinker A, Carter J, Petru E, Nicklin J, Quinn M, et al. Malignant transformation within ovarian dermoid cysts. International Journal of Gynecological Cancer. 2010; 20: 75–81.
[18] Hackethal A, Brueggmann D, Bohlmann MK, Franke FE, Tinneberg H, Münstedt K. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. The Lancet Oncology. 2008; 9: 1173–1180.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top